Imatinib Mesylate API Market Report – Research, Industry Analysis Reports and Market Demands

Global Imatinib Mesylate API Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029

Request for Sample of this report

Buy now

Table of Content

1 Market Overview

1.1 Product Overview and Scope of Imatinib Mesylate API
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
- 1.3.1 Overview: Global Imatinib Mesylate API Consumption Value by Type: 2018 Versus 2022 Versus 2029
- 1.3.2 Purity≥99%
- 1.3.3 Purity<99%
1.4 Market Analysis by Application
- 1.4.1 Overview: Global Imatinib Mesylate API Consumption Value by Application: 2018 Versus 2022 Versus 2029
- 1.4.2 Tablet
- 1.4.3 Capsule
1.5 Global Imatinib Mesylate API Market Size & Forecast
- 1.5.1 Global Imatinib Mesylate API Consumption Value (2018 & 2022 & 2029)
- 1.5.2 Global Imatinib Mesylate API Sales Quantity (2018-2029)
- 1.5.3 Global Imatinib Mesylate API Average Price (2018-2029)

2 Manufacturers Profiles

3 Competitive Environment: Imatinib Mesylate API by Manufacturer

3.1 Global Imatinib Mesylate API Sales Quantity by Manufacturer (2018-2023)
3.2 Global Imatinib Mesylate API Revenue by Manufacturer (2018-2023)
3.3 Global Imatinib Mesylate API Average Price by Manufacturer (2018-2023)
3.4 Market Share Analysis (2022)
- 3.4.1 Producer Shipments of Imatinib Mesylate API by Manufacturer Revenue ($MM) and Market Share (%): 2022
- 3.4.2 Top 3 Imatinib Mesylate API Manufacturer Market Share in 2022
- 3.4.2 Top 6 Imatinib Mesylate API Manufacturer Market Share in 2022
3.5 Imatinib Mesylate API Market: Overall Company Footprint Analysis
- 3.5.1 Imatinib Mesylate API Market: Region Footprint
- 3.5.2 Imatinib Mesylate API Market: Company Product Type Footprint
- 3.5.3 Imatinib Mesylate API Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

4.1 Global Imatinib Mesylate API Market Size by Region
- 4.1.1 Global Imatinib Mesylate API Sales Quantity by Region (2018-2029)
- 4.1.2 Global Imatinib Mesylate API Consumption Value by Region (2018-2029)
- 4.1.3 Global Imatinib Mesylate API Average Price by Region (2018-2029)
4.2 North America Imatinib Mesylate API Consumption Value (2018-2029)
4.3 Europe Imatinib Mesylate API Consumption Value (2018-2029)
4.4 Asia-Pacific Imatinib Mesylate API Consumption Value (2018-2029)
4.5 South America Imatinib Mesylate API Consumption Value (2018-2029)
4.6 Middle East and Africa Imatinib Mesylate API Consumption Value (2018-2029)

5 Market Segment by Type

5.1 Global Imatinib Mesylate API Sales Quantity by Type (2018-2029)
5.2 Global Imatinib Mesylate API Consumption Value by Type (2018-2029)
5.3 Global Imatinib Mesylate API Average Price by Type (2018-2029)

6 Market Segment by Application

6.1 Global Imatinib Mesylate API Sales Quantity by Application (2018-2029)
6.2 Global Imatinib Mesylate API Consumption Value by Application (2018-2029)
6.3 Global Imatinib Mesylate API Average Price by Application (2018-2029)

7 North America

7.1 North America Imatinib Mesylate API Sales Quantity by Type (2018-2029)
7.2 North America Imatinib Mesylate API Sales Quantity by Application (2018-2029)
7.3 North America Imatinib Mesylate API Market Size by Country
- 7.3.1 North America Imatinib Mesylate API Sales Quantity by Country (2018-2029)
- 7.3.2 North America Imatinib Mesylate API Consumption Value by Country (2018-2029)
- 7.3.3 United States Market Size and Forecast (2018-2029)
- 7.3.4 Canada Market Size and Forecast (2018-2029)
- 7.3.5 Mexico Market Size and Forecast (2018-2029)

8 Europe

8.1 Europe Imatinib Mesylate API Sales Quantity by Type (2018-2029)
8.2 Europe Imatinib Mesylate API Sales Quantity by Application (2018-2029)
8.3 Europe Imatinib Mesylate API Market Size by Country
- 8.3.1 Europe Imatinib Mesylate API Sales Quantity by Country (2018-2029)
- 8.3.2 Europe Imatinib Mesylate API Consumption Value by Country (2018-2029)
- 8.3.3 Germany Market Size and Forecast (2018-2029)
- 8.3.4 France Market Size and Forecast (2018-2029)
- 8.3.5 United Kingdom Market Size and Forecast (2018-2029)
- 8.3.6 Russia Market Size and Forecast (2018-2029)
- 8.3.7 Italy Market Size and Forecast (2018-2029)

9 Asia-Pacific

9.1 Asia-Pacific Imatinib Mesylate API Sales Quantity by Type (2018-2029)
9.2 Asia-Pacific Imatinib Mesylate API Sales Quantity by Application (2018-2029)
9.3 Asia-Pacific Imatinib Mesylate API Market Size by Region
- 9.3.1 Asia-Pacific Imatinib Mesylate API Sales Quantity by Region (2018-2029)
- 9.3.2 Asia-Pacific Imatinib Mesylate API Consumption Value by Region (2018-2029)
- 9.3.3 China Market Size and Forecast (2018-2029)
- 9.3.4 Japan Market Size and Forecast (2018-2029)
- 9.3.5 Korea Market Size and Forecast (2018-2029)
- 9.3.6 India Market Size and Forecast (2018-2029)
- 9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
- 9.3.8 Australia Market Size and Forecast (2018-2029)

10 South America

10.1 South America Imatinib Mesylate API Sales Quantity by Type (2018-2029)
10.2 South America Imatinib Mesylate API Sales Quantity by Application (2018-2029)
10.3 South America Imatinib Mesylate API Market Size by Country
- 10.3.1 South America Imatinib Mesylate API Sales Quantity by Country (2018-2029)
- 10.3.2 South America Imatinib Mesylate API Consumption Value by Country (2018-2029)
- 10.3.3 Brazil Market Size and Forecast (2018-2029)
- 10.3.4 Argentina Market Size and Forecast (2018-2029)

11 Middle East & Africa

11.1 Middle East & Africa Imatinib Mesylate API Sales Quantity by Type (2018-2029)
11.2 Middle East & Africa Imatinib Mesylate API Sales Quantity by Application (2018-2029)
11.3 Middle East & Africa Imatinib Mesylate API Market Size by Country
- 11.3.1 Middle East & Africa Imatinib Mesylate API Sales Quantity by Country (2018-2029)
- 11.3.2 Middle East & Africa Imatinib Mesylate API Consumption Value by Country (2018-2029)
- 11.3.3 Turkey Market Size and Forecast (2018-2029)
- 11.3.4 Egypt Market Size and Forecast (2018-2029)
- 11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
- 11.3.6 South Africa Market Size and Forecast (2018-2029)

12 Market Dynamics

12.1 Imatinib Mesylate API Market Drivers
12.2 Imatinib Mesylate API Market Restraints
12.3 Imatinib Mesylate API Trends Analysis
12.4 Porters Five Forces Analysis
- 12.4.1 Threat of New Entrants
- 12.4.2 Bargaining Power of Suppliers
- 12.4.3 Bargaining Power of Buyers
- 12.4.4 Threat of Substitutes
- 12.4.5 Competitive Rivalry
12.5 Influence of COVID-19 and Russia-Ukraine War
- 12.5.1 Influence of COVID-19
- 12.5.2 Influence of Russia-Ukraine War

13 Raw Material and Industry Chain

13.1 Raw Material of Imatinib Mesylate API and Key Manufacturers
13.2 Manufacturing Costs Percentage of Imatinib Mesylate API
13.3 Imatinib Mesylate API Production Process
13.4 Imatinib Mesylate API Industrial Chain

14 Shipments by Distribution Channel

14.1 Sales Channel
- 14.1.1 Direct to End-User
- 14.1.2 Distributors
14.2 Imatinib Mesylate API Typical Distributors
14.3 Imatinib Mesylate API Typical Customers

15 Research Findings and Conclusion

16 Appendix

16.1 Methodology
16.2 Research Process and Data Source

Description

According to our (Global Info Research) latest study, the global Imatinib Mesylate API market size was valued at USD million in 2022 and is forecast to a readjusted size of USD million by 2029 with a CAGR of % during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
This report is a detailed and comprehensive analysis for global Imatinib Mesylate API market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
Key Features:
Global Imatinib Mesylate API market size and forecasts, in consumption value ($ Million), sales quantity (Tons), and average selling prices (US$/Ton), 2018-2029
Global Imatinib Mesylate API market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Tons), and average selling prices (US$/Ton), 2018-2029
Global Imatinib Mesylate API market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (Tons), and average selling prices (US$/Ton), 2018-2029
Global Imatinib Mesylate API market shares of main players, shipments in revenue ($ Million), sales quantity (Tons), and ASP (US$/Ton), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Imatinib Mesylate API
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Imatinib Mesylate API market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Aurobindo Pharma Ltd, Formosa Laboratories Inc, Cadila Healthcare Ltd, Laurus Labs Ltd and Msn Laboratories Private Ltd, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Market Segmentation
Imatinib Mesylate API market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Purity≥99%
Purity<99%
Market segment by Application
Tablet
Capsule
Major players covered
Aurobindo Pharma Ltd
Formosa Laboratories Inc
Cadila Healthcare Ltd
Laurus Labs Ltd
Msn Laboratories Private Ltd
Intas Pharmaceuticals Ltd
Zydus Lifesciences Ltd
Hetero Labs Ltd
Shilpa Pharma Lifesciences Ltd
Teva Pharmaceutical Industries Ltd
Cipla Ltd
Acebright India Pharma Private Ltd
Fis Fabbrica Italiana Sintetici Spa
Dr Reddys Laboratories Ltd
Natco Pharma Ltd
Sun Pharmaceutical Industries Ltd
Reliance Life Sciences Pvt Ltd
Zhejiang Jiuzhou Pharmaceutical Co Ltd
Tai Heng Industry Group Co Ltd
Shandong Anxin Pharmaceutical Co Ltd
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Imatinib Mesylate API product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Imatinib Mesylate API, with price, sales, revenue and global market share of Imatinib Mesylate API from 2018 to 2023.
Chapter 3, the Imatinib Mesylate API competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Imatinib Mesylate API breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2018 to 2029.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2018 to 2029.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2022.and Imatinib Mesylate API market forecast, by regions, type and application, with sales and revenue, from 2024 to 2029.
Chapter 12, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War.
Chapter 13, the key raw materials and key suppliers, and industry chain of Imatinib Mesylate API.
Chapter 14 and 15, to describe Imatinib Mesylate API sales channel, distributors, customers, research findings and conclusion.

Buy now